Ranking Profile - Global Blood Therapeutics Inc

Introduction

Global Blood Therapeutics Inc (GBT), a subsidiary of Pfizer Inc, is a clinical-stage biopharmaceutical company. The company discovers and develops oxbryta (voxelotor), inclacumab and GBT601. Its products are used for the treatment of various therapeutic areas which includes sickle cell disease (SCD), chronic vaso-occlusive crisis (VOC) prevention, acute VOC re-admission prevention and hemolytic anemia. GBT offers products in tablet form for both children and adults under the brand name Oxbryta. The company also focuses on the development of therapies that are in preclinical clinical stages for the treatment of acute and chronic hypoxemic pulmonary disorders. GBT is headquartered in South San Francisco, California, the US.